Avastin saga reveals debate over clinical trial endpoints.
Sharan Prakash
SP
Sharma
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D018572:Disease-Free Survival; D017277:Drug Approval / Q000379:methods*; D005060:Europe; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D020360:Neoadjuvant Therapy / Q000379:methods; D011358:Product Surveillance, Postmarketing; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab